N-(4-cyano-3-methoxypyridin-2-yl)-N-[(3R,6R)-6-methylpiperidin-3-yl]-2-pyrimidin-2-ylthiophene-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: N-(4-cyano-3-methoxypyridin-2-yl)-N-[(3R,6R)-6-methylpiperidin-3-yl]-2-pyrimidin-2-ylthiophene-3-carboxamide
• 化学式: C₂₂H₂₂N₆O₂S
• 分子量: 434.5
• InChiKey: RBUZENAUSHZPNG-GDBMZVCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] 2-PYRIDYLAMINO-4-NITRILE-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE 2-PYRIDYLAMINO-4-NITRILE-PIPÉRIDINYL, ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014085208A1

  公开（公告）日：2014-06-05

  The present invention is directed to 2-pyridylamino-4-nitrile-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridylamino-4-nitrile-piperidinyl compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶基氨基-4-硝基-哌啶基化合物，其是促进睡眠激素受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶基氨基-4-硝基-哌啶基化合物治疗或预防涉及促进睡眠激素受体的神经和精神疾病和疾病的用途。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗涉及促进睡眠激素受体的疾病中的用途。
• 2-PYRIDYLAMINO-4-NITRILE-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2925321A1

  公开（公告）日：2015-10-07
• USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3223803A1

  公开（公告）日：2017-10-04
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3218007A1

  公开（公告）日：2017-09-20
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3454857A1

  公开（公告）日：2019-03-20